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Abstract
Objective—Oxidative stress is integral to the development of endothelial dysfunction and
cardiovascular disease. As NRF2 is a key transcription factor in antioxidant defense, we aimed to
determine whether polymorphisms within the promoter region of the gene encoding NRF2
(NFE2L2) would significantly modify vasodilator responses in humans.
Methods—Associations between the – 653A/G (rs35652124), – 651G/A (rs6706649), and –
617C/A (rs6721961) polymorphisms within the NFE2L2 promoter and vascular function were
evaluated in healthy African-American (n= 64) and white (n= 184) individuals. Forearm blood
flow (FBF) was measured by strain-gauge venous occlusion plethysmography at baseline and in
response to incremental doses of bradykinin or sodium nitroprusside. Forearm vascular resistance
(FVR) was calculated as the mean arterial pressure/FBF.
Results—In African Americans, – 653G variant allele carriers had significantly lower FBF and
higher FVR under basal conditions as well as in response to bradykinin or sodium nitroprusside
compared with wild-type individuals (P< 0.05 for each comparison). In whites, although no
significant associations were observed with the – 653A/G genotype, – 617A variant allele carriers
had significantly higher FVR at baseline and in response to bradykinin or sodium nitroprusside
compared with wild-type individuals (P < 0.05 for each comparison). The – 651G/A
polymorphism was not associated with vasodilator responses in either racial group.
Conclusion—Polymorphisms within the NFE2L2 promoter were associated with impaired
forearm vasodilator responses in an endothelial-independent manner, suggesting an important role
of NRF2 in the regulation of vascular function in humans.
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Introduction
Endothelial dysfunction is a common and early feature of vascular disease that is manifested
by impaired peripheral and coronary artery vasodilator responses, and is present in patients
with hypertension, hypercholesterolemia, and diabetes mellitus, and in older patients [1,2].
In particular, reduced vasodilator responses occur early in atherogenesis, before
angiographic evidence of disease [3], and is significantly associated with the development of
atherosclerosis and clinical events such as myocardial infarction and stroke [4,5]. Oxidative
stress is an integral mediator of the development of endothelial dysfunction and
consequently the development and progression of atherosclerosis [1,2].
Nuclear factor E2-related factor 2 (NRF2) is a member of the basic leucine zipper (bZip)
transcription factors [6]. NRF2 regulates cellular defense against various detrimental stresses
including oxidative stress by controlling the basal and inducible expression of antioxidant
genes, phase II detoxifying enzymes, transporters, scavenger receptors, chaperone proteins,
and transcription factors [7–9]. NRF2 is ubiquitously expressed in the cardiovascular
system, where it plays a key role in defense against cytotoxic assault [10,11]. In human
aortic endothelial cells, NRF2 overexpression inhibited hydrogen peroxide-induced
cytotoxicity, as well as induction of monocyte chemoattractant protein-1 and vascular cell
adhesion molecule-1 expression and monocyte adhesion in response to the proinflammatory
cytokine tumor necrosis factor [12]. NRF2 activation also reversed the dysfunction of
endothelial cells induced by hyperglycemia [13]. Moreover, induction of NRF2-dependent
antioxidant gene expression in response to oxidized phospholipids was lower in the carotid
arteries of Nrf2 knockout compared with wild-type mice, suggesting a potential
antiatherogenic effect of NRF2 [14].
In humans, three single nucleotide polymorphisms within the promoter region of the gene
encoding NRF2 (NFE2L2) were identified recently [ – 653A/G (rs35652124), – 651G/A
(rs6706649), and – 617C/A (rs6721961)], and each minor allele showed significantly
reduced NFE2L2 promoter activity in transfected A549 human alveolar adenocarcinoma
cells in vitro [15]. Moreover, – 617A variant allele carriers showed a significantly higher
risk of acute lung injury, an oxidative stress-mediated condition [15]. In contrast, the role of
NRF2 in the regulation of vascular function in humans remains largely unexplored. Because
of the integral role of NRF2 in antioxidant defense, and the impact of oxidative stress on the
development and severity of endothelial dysfunction, we hypothesized that functionally
relevant polymorphisms within the promoter region of NFE2L2 would significantly modify
endothelium-dependent and endothelium-independent vasodilator responses in humans.
Consequently, the objective of the present investigation was to evaluate the impact of the
NFE2L2 – 653A/G, –651G/A, and –617C/A polymorphisms on forearm vasodilator
responses to bradykinin and sodium nitroprusside.
Methods
Participants
Healthy volunteers (n=248) who participated in studies that evaluated endothelium-
dependent and endothelium-independent forearm vasodilator responses to bradykinin and
sodium nitroprusside, respectively, were included [16]. Participants were classified as either
African Americans (n=64) or whites (n=184). Each participant was asked to self-report their
Marczak et al. Page 2













race and indicate whether all four of their grandparents had self-defined as the same race. If
the participants and all four of their grandparents did not self-define as the same race, they
were excluded from the study. All participants gave written informed consent and underwent
a history, physical examination, laboratory screening, and electrocardiogram. Patients with
significant cardiovascular, renal, pulmonary, endocrine, or hematological disease were
excluded. All participants were within 30% of their ideal body weight and none were taking
medications, including angiotensin-converting enzyme inhibitors. Pregnancy was an
exclusion criterion in women of childbearing potential, and was determined by the
measurement of urine β-human chorionic gonadotropin. The protocol was approved by the
Institutional Review Board at each institution and was conducted according to the
Declaration of Helsinki.
Phenotype assessment
Studies were performed in a temperature-controlled room in the morning after an overnight
fast, as described previously [16,17]. A 20-G polyurethane catheter was inserted into the
brachial artery of the nondominant arm, and arterial catheter patency was maintained by an
infusion of 0.9% sodium chloride at a rate of 1 ml/min. Participants were allowed to rest for
30 min before baseline measurements and between drug infusions. Heart rate and blood
pressure were monitored continuously in the contralateral arm throughout the infusion
protocol using an automated blood pressure cuff (GE Medical Systems, Tampa, Florida,
USA). Forearm blood flow (FBF) was measured using strain-gauge venous occlusion
plethysmography (DE Hokanson, Bellevue, Washington, USA) at baseline and in response
to incremental doses of bradykinin (100 and 200 ng/min; Clinalfa AG, Läufelfingen,
Switzerland). Sodium nitroprusside (1.6, 3.2, and 6.4 μg/min; Gensia Siccor
Pharmaceuticals, Irvine, California, USA) was administered to 231 participants as an
endothelium-independent control. Each drug dose was infused for 5min, and FBF was
measured during the last 2 min of each drug infusion protocol. The sequence of drug
administration was randomized to avoid an order effect. FBF is expressed in ml/100 ml of
volume of tissue/minute. Forearm vascular resistance (FVR) is calculated as the ratio of the
mean arterial pressure/FBF and expressed in mmHg/ml/100 ml of volume of tissue/minute.
Evaluation of FBF following an intra-arterial infusion of bradykinin and sodium
nitroprusside, respectively, is a well-established method to assess endothelial-dependent and
endothelial-independent vasodilator responses in humans [1]. Importantly, these peripheral
vascular phenotypes correlate with vasodilator responses in coronary arteries and predict the
risk of developing cardiovascular disease [5].
Genotyping
DNA was isolated from whole-blood samples by a modified phenol–chloroform extraction.
The – 653A/G, – 651G/A, and – 617C/A genotypes were determined by direct sequencing
of the − 738 to − 461 region within the NFE2L2 promoter, as described previously [15].
Initial PCR products were generated with the Epicentre Failsafe system (Epicentre
Biotechnologies, Madison, Wisconsin, USA) using 50 ng of genomic DNA, 1 μmol/l each
of forward (5′-GACCACTCTCCGACCTAAAGG-3′) and reverse primer (5′-
CGAGATAAAGAGTTGTTTGCGAA-3′), 12.5 μl of Failsafe buffer E, and 0.25U of
Failsafe enzyme mix. The PCR conditions were as follows: initial denaturation at 95°C for 4
min, followed by 35 cycles of 95°C for 1 min, 56°C for 1 min, 72°C for 1 min, and a final
extension at 72°C for 8 min. Products were purified using the GenElute PCR cleanup kit
(Sigma Chemical Co., St Louis, Missouri, USA) and a portion was run on 3% agarose gels
to confirm amplification. Sequencing reactions were carried out using the Big Dye
terminator kit and analyzed on a Perkin Elmer ABI 3100 Automated DNA Sequencer
(Applied Biosystems, Foster City, California, USA). Ambiguous samples were verified
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using overlapping reads with an internal primer (5′-CTTTTA
TCTCACTTTACCGCCC-3′). All samples were randomized and genotyped, and the results
were read by two independent researchers with 100% concordance.
Transient transfection reporter gene assay
The impact of each polymorphism on the activity of the NFE2L2 promoter in endothelial
cells, under both basal and stimulated conditions, was assessed using reporter gene assays.
As described previously [15], constructs containing the – 653G, –651A, and – 617A variant
alleles were generated by cloning the −727 to +131 region of the NFE2L2 promoter into a
pGL3 vector upstream of the luciferase reporter gene. Sequence-verified constructs were
transiently transfected into human microvascular endothelial cells (HMVEC-L, Lonza Inc.,
Walkersville, Maryland, USA) and maintained in media supplemented with 10% fetal
bovine serum (Sigma). DNA constructs were transfected using the Amaxa HMVEC-L
nucleofector kit (Lonza Inc.) according to the manufacturer’s specifications. HMVEC cells
grown to 70–80% confluence on 12-well transwell plates were cotransfected with 0.5 μg of
the promoter construct, or an empty (promoter-less) pGL3 vector, and 5 μg of pRL-TK
(renilla) DNA as a transfection efficiency internal control. Twenty-four hours after
transfection, cells were incubated with vehicle (medium), bradykinin (0.01 or 0.1 mmol/l),
sodium nitroprusside (0.1 mmol/l), or hydrogen peroxide (0.1mmol/l) for an additional 24 h
and reporter gene activity was measured using the Promega Dual-Luciferase reporter assay
system (Promega Corp., Madison, Wisconsin, USA). The concentrations were selected after
the completion of preliminary experiments that aimed to induce a two- to three-fold
upregulation in promoter activity (data not shown). Luciferase activity was measured in
three independent samples, and experiments were repeated in triplicate.
Statistical analysis
Race-stratified allele frequencies were calculated and evaluated for deviation from Hardy–
Weinberg Equilibrium (HWE) by comparing the observed and the expected frequencies
using the χ2-test. HWE and pairwise linkage disequilibrium (LD) statistics were calculated
using Haploview 4.2. Differences in the baseline characteristics among the genotype groups
for continuous variables were determined using Student’s t-test or analysis of variance
(ANOVA), where appropriate. A χ2-test was used to compare categorical variables.
Variables that were not normally distributed, including FBF and FVR, were log transformed
before analysis.
Differences in FBF and FVR were evaluated by general linear model-repeated measures
ANOVA in which the within-participant variable was bradykinin or sodium nitroprusside
dose and the between-participant variable was genotype group. Because of previously
reported racial differences in vasodilator responses in this and other cohorts [16,18,19], all
analyses were stratified by race. Genotype frequencies governed the appropriate model to
use. An additive mode of inheritance was initially applied for each polymorphism, but was
retained only for the – 653A/G polymorphism in whites. Because of the low number of
participants homozygous for variant alleles, a dominant mode of inheritance was used in all
the other comparisons. In instances where the general linear model-repeated measures
ANOVA was statistically significant (P<0.05), a post-hoc Scheffe’s test was utilized to
evaluate between-group differences at each dose. A P-value less than 0.05 was used to
determine statistical significance. Data are presented as mean±SEM unless otherwise
indicated. Statistical analyses were performed using SAS 9.1 for Windows (SAS Institute
Inc., Cary, North Carolina, USA).
To minimize the impact of the multiple statistical tests carried out, the false discovery rate q-
value was estimated using QVALUE for each repeated-measures ANOVA test [20]. The q-
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value is defined as the expected proportion of statistical tests considered significant that are
actually false positives. Only q-values for statistically significant findings (P<0.05) are
presented. Post-hoc power calculations were completed using QUANTO [21].
In the reporter gene experiments, data were expressed relative to the wild-type vehicle
(control) group, and differences across genotype and treatment were evaluated using an
ANOVA and the Student–Newman–Keuls a posteriori comparisons of means (SigmaPlot
12, Systat Software Inc., Chicago, Illinois, USA). A two-sided P-value of less than 0.05 was
considered statistically significant.
Results
Participant characteristics and NFE2L2 genotype distribution
Race-stratified participant characteristics are presented in Table 1. In comparison with the
white participants, the African-American cohort had significantly higher blood pressure,
FVR, and BMI, and included significantly more women. All other characteristics were not
significantly different between groups.
Race-stratified genotype distributions and allelic frequencies for each polymorphism are
presented in Table 2. The – 653G and – 617A allele frequencies were significantly higher in
whites compared with African Americans; however, the – 651A allele frequency did not
differ between racial groups. The genotype distributions for each polymorphism were in
HWE within each racial group (P>0.20 for each comparison). No evidence of pairwise LD
was observed between the three polymorphisms in either racial group (r2<0.01 in African
Americans, r2<0.07 in whites for all comparisons).
No statistically significant differences in age, sex, cigarette smoking status, BMI, or resting
blood pressure were observed across any of the genotype groups (see Supplemental Tables
1, 2, and 3, Supplemental digital content 1, http://links.lww.com/FPC/A482, which provides
race-stratified comparisons of participant characteristics by – 653A/G, –651G/A, and –
617C/A genotypes, respectively).
NFE2L2 genotype and vasodilator responses to bradykinin and sodium nitroprusside
An infusion of bradykinin (100 and 200 ng/min) and sodium nitroprusside (1.6, 3.2, and 6.4
μg/min) caused a dose-dependent increase in FBF and decrease in FVR in both African
Americans and whites (Figs 1–3).
– 653A/G
In African Americans, – 653G variant allele carriers had significantly lower baseline FBF
(2.7±1.1 vs. 4.1±1.1 ml/ 100 ml tissue/min; P<0.001) and higher FVR (31.1±1.1 vs.
22.5±1.1 mmHg/ml/100ml tissue/min; P=0.006) compared with wild-type (A/A)
individuals, respectively. The vasodilator response to bradykinin was significantly
associated with the – 653A/G genotype, such that FBF was significantly lower (Fig. 1a,
P=0.003, q=0.020) and FVR was significantly higher (Fig. 1b, P=0.040, q=0.130) in – 653G
variant allele carriers relative to wild-type individuals. Statistically significant associations
between the – 653A/G genotype and both FBF (Fig. 1c, P<0.001, q=0.010) and FVR (Fig.
1d, P=0.003, q=0.020) were also observed after the administration of sodium nitroprusside.
In whites, the differences in basal FBF (3.6±1.1 vs. 4.0±1.1ml/100ml tissue/min; P=0.184)
and FVR (22.7±1.1 vs. 20.8±1.1 mmHg/ml/100 ml tissue/min; P=0.084) between – 653G
variant allele carriers and wild-type individuals, respectively, were less substantial than
those observed in African Americans and were not statistically significant. In contrast to the
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significant associations observed in African Americans, the – 653A/G genotype was not
significantly associated with either FBF or FVR after the administration of either bradykinin
or sodium nitroprusside in whites (Fig. 2). Similar results were obtained using a dominant
model of inheritance (data not shown).
– 651G/A
No significant differences in resting FBF (P=0.445 and 0.123) and FVR (P=0.340 and
0.196) were observed across the – 651G/A genotype in either African Americans or whites,
respectively (see Supplemental Table 2, Supplemental digital content 1, http://
links.lww.com/FPC/A482). Moreover, no significant association between the – 651G/A
genotype and the vasodilator response to either bradykinin (FBF: P=0.119, FVR: P=0.225)
or sodium nitroprusside (FBF: P=0.772, FVR: P=0.731) was observed in whites (see
Supplemental Fig. 1, Supplemental digital content 2, http://links.lww.com/FPC/A483, which
shows the forearm vasodilator responses across the – 651G/A genotype). Similar results
were observed in African Americans, although only seven – 651A variant allele carriers
were identified (see Supplemental Fig. 2, Supplemental digital content 2, http://
links.lww.com/FPC/A483).
– 617C/A
In whites, – 617A variant allele carriers had lower baseline FBF (3.4±1.1 vs. 3.9±1.0ml/100
ml tissue/min; P=0.076) and higher FVR (24.9±1.1 vs. 21.0±1.0mmHg/ml/100 ml tissue/
min; P=0.035) compared with wild-type (C/C) individuals, respectively; however, only the
FVR difference was statistically significant. Vasodilator responses to bradykinin and sodium
nitroprusside were also associated with the – 617C/A genotype in whites. Although the
difference in FBF did not reach statistical significance (Fig. 3a, P=0.076 and Fig. 3c,
P=0.092, respectively), – 617A variant allele carriers showed significantly higher FVR (Fig.
3b, P=0.030, q=0.120 and Fig. 3d, P=0.026, q=0.120, respectively) compared with wild-type
individuals. Statistical comparisons were not completed in African Americans as only two –
617A variant allele carriers were identified.
Functional significance of the NFE2L2 promoter polymorphisms in vitro
NFE2L2 promoter constructs were assessed in transiently transfected HMVEC cells. Wild-
type and variant NFE2L2 constructs were used to assess the effects of each variant allele on
the functional activity of the promoter under basal conditions and following stimulation with
bradykinin, sodium nitroprusside, and hydrogen peroxide. Under basal conditions, HMVEC
cells transfected with variant promoter constructs differed significantly from cells
transfected with the wild-type promoter construct (P<0.05 vs. wild type for all constructs,
Fig. 4). Although moderately lower transcriptional activity was observed in vehicle-treated
cells bearing the variant – 653G or – 651A constructs (27 and 23% reduction, respectively,
compared with the wild type), the most substantial effect was observed with – 617A (42%
reduction compared with the wild type; P<0.05 vs. – 653G and – 651A). Bradykinin, sodium
nitroprusside, and hydrogen peroxide each significantly increased the transcriptional activity
for all constructs (P<0.05 vs. vehicle, Fig. 4). The – 653G, – 651A, and – 617A variants
each significantly attenuated the activation of luciferase activity irrespective of the stimulus
(P<0.05 vs. the wild type for all comparisons, Fig. 4).
Discussion
NRF2 is a key regulator of cardiovascular homeostasis through the suppression of oxidative
stress assault [10–13,22,23], which is a major contributor to the development and
progression of vascular dysfunction and cardiovascular disease in humans [2,5]. Although
polymorphisms in the NFE2L2 gene have recently been associated with oxidative stress-
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related and inflammation-related diseases and drug-induced phenotypes in humans
[15,24,25], the impact of NFE2L2 polymorphisms on vascular function has not been studied
to date. The current study examined the effects of three polymorphisms (– 653A/G, –651G/
A, and – 617C/A) within the NFE2L2 promoter region on forearm vasodilator responses to
bradykinin (endothelium-dependent) and sodium nitroprusside (endothelium-independent)
in healthy African-American and white participants. This study identified a significant
association between genetic variants in NFE2L2 and these established peripheral vascular
phenotypes [1], which have been shown to correlate with vasodilator responses in coronary
arteries and predict the risk of developing cardiovascular disease in humans [5].
Specifically, African-American – 653G variant allele carriers had significantly lower FBF
and higher FVR under basal conditions as well as in response to each vasodilator compared
with wild-type A/A individuals. Similar associations were observed with the – 617A variant
allele in whites, who had lower FBF and significantly higher FVR under basal conditions
and in response to each vasodilator compared with wild-type C/ C individuals. Similar
genotype–phenotype relationships were observed in response to bradykinin and sodium
nitroprusside, suggesting that the mechanism underlying the link between genetic variation
in NRF2 and vascular function in humans is endothelial independent.
The results from the transient transfection reporter gene assays show that the – 653G, –
651A, and – 617A variant alleles each reduce NFE2L2 promoter activity in endothelial cells
under both basal and stimulated conditions. Consequently, we speculate that these
polymorphisms within the NFE2L2 promoter may also be associated with chronically lower
vascular NRF2 expression in vivo. Indeed, it is well established that polymorphisms within
regulatory regions and enhancer elements of a given gene can exert a profound effect on
transcription efficiency and thus alter the levels of mRNA and protein [26]; however, the
reporter gene assay experiments do not allow an assessment of whether the variant alleles
impact the occurrence of a more physiologically relevant phenotype such as oxidative stress.
Moreover, the impact of factors that regulate NFE2L2 at the transcriptional level on NRF2
function in vivo remains unclear. NRF2 is associated with Kelch-like ECH associating
protein 1 (KEAP1) and is predominantly localized in the cytoplasm of unstressed cells [8,9].
Oxidative stress disrupts the sequestration of NRF2 by KEAP1 and allows NRF2
translocation to the nucleus, where it regulates the basal and inducible expression of more
than 200 known genes [8,9]. In preclinical models, NRF2 deficiency reduces the expression
of several antioxidant genes, enhances the expression levels of proinflammatory cytokines,
chemokines, and several genes involved in cell proliferation, adhesion, migration, and
differentiation, and consequently plays an important role in the regulation of endothelial and
vascular smooth muscle cell growth and vascular remodeling [7,12,22]. In addition, NRF2
regulates cardiac remodeling and hypertrophy, and slows the onset of cardiac dysfunction in
response to pathological hemodynamic stress [23]. Collectively, these studies suggest that
genetic predisposition to chronically lower NRF2 expression in humans, secondary to the
presence of polymorphisms within the NFE2L2 promoter that lower transcriptional activity,
would be predicted to compromise antioxidant defense systems and result in prolonged
oxidative stress, progressive vascular remodeling, and ultimately impaired endothelium-
independent vasodilator responses.
The observed associations between – 653A/G and – 617C/A genotypes and vascular
function in African Americans and whites, respectively, were consistent with the in-vitro
data and this functional relationship. In contrast, no differences in vasodilator responses
were observed in white – 653G variant allele carriers or – 651A variant allele carriers in
either racial group. Although the underlying mechanisms remain unclear, the lack of an
association between the – 653A/G polymorphism and vasodilator responses in whites could
be because of, at least in part, underlying racial differences in vascular function [18,19] and
oxidative stress level [27]. It is well established that African Americans have a higher
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prevalence of hypertension and decreased vasodilatory responses to endothelium-dependent
or endothelium-independent stimuli compared with white populations [18]. Indeed, racial
differences in forearm vasodilator responses were observed in the cohort under investigation
[16,17]. Predisposition to higher vascular resistance in African Americans leads to increased
shear stress on endothelial cells, which activates NAD(P)H oxidase-mediated reactive
oxygen species formation in the vasculature [11,23]. Consequently, NAD(P)H oxidase
expression is higher and the steady-state balance of nitric oxide/superoxide/peroxynitrite in
endothelial cells is shifted in favor of reactive oxygen species in African Americans, which
is associated with an impaired vasodilatory capacity [27]. Therefore, we hypothesize that the
blunted antioxidant effect associated with the NFE2L2 promoter polymorphisms may be
most relevant in African Americans, who are prone to a higher degree of oxidative stress
and impaired vascular function compared with white populations. Indeed, this relationship is
consistent with our observation that African-American, but not white, – 653G variant allele
carriers showed significantly lower FBF and higher FVR at baseline and in response to
bradykinin and sodium nitroprusside compared with wild-type individuals despite the
modest effects of the – 653G variant on NFE2L2 transcriptional activity in endothelial cells
in vitro.
Despite examining the vascular effects of NRF2 polymorphisms in one of the largest cohorts
that directly measured vasodilatory responses to infused agonists, the relatively small
sample size, particularly in the African Americans studied (n=64), represents a limitation.
Although there was a modest degree of power to detect a 30% difference in FVR in African
Americans across the – 653A/G genotype at an α=0.05 level (β=0.64), only seven – 651A
and two – 617A variant allele carriers were identified and these data should be interpreted
with caution. In whites, however, there was ample power to detect a 30% difference in FVR
across the – 653A/G (β=0.99), – 651G/A (β=0.90), and – 617C/A (β=0.92) genotypes at an
α=0.05 level. Therefore, we conclude that a clinically significant association between the –
653A/G and – 651G/A genotypes and vasodilator responses does not exist in healthy whites.
Although the underlying mechanism remains unclear, the modest effect of the – 653G and –
651A variants on NFE2L2 transcription in vitro may not have been large enough to confer
an observable phenotype in whites, who are less prone to oxidative stress and vascular
dysfunction compared with African-American populations [27]. In contrast, the – 617A
variant, which showed the most substantial reduction in luciferase activity in vitro and has
been associated previously with acute lung injury in humans [15], was associated with
significantly higher FVR in whites. We acknowledge that the lack of in-vivo oxidative stress
biomarker measurements in this population, which could have provided a functional insight
into the observed polymorphism-specific and race-specific associations between NRF2 and
vascular function, is a major limitation of our work. In addition, the current population
included healthy volunteers. This could reduce generalization of the observed associations
with other populations with enhanced oxidative stress and at a high risk of developing
cardiovascular disease, such as individuals with the metabolic syndrome and diabetes, and
cigarette smokers. Future studies are warranted to elucidate the contribution of oxidative
stress toward the observed NRF2 genotype–vascular function phenotype relationships.
Finally, multiple statistical tests were carried out in this genotype–phenotype analysis, which
could potentially lead to false-positive associations. To minimize the impact of multiple
comparisons, a false discovery rate q-value was calculated for each comparison [20,21]. As
all q-values were estimated to be less than 0.15, and the NFE2L2 – 653G and – 617A
variants have been associated recently with other oxidative stress-related phenotypes in
humans [15,24,25], a higher level of confidence exists in the associations reported.
However, it cannot be ruled out that these are simply markers in LD with the true causative
loci. Importantly, these associations will ultimately require validation in an independent
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population to confirm the presence of a functional relationship between genetic variants in
NFE2L2 and vascular function in humans.
Conclusion
Genetic variation within the NFE2L2 promoter is associated with impaired forearm
vasodilator responses in an endothelial-independent manner, suggesting an important role
for NRF2 in the regulation of vascular function in humans. Further studies are necessary to
validate the impact of these polymorphisms in the NFE2L2 promoter on NRF2 expression,
oxidative stress, vascular function, and the risk of cardiovascular disease in humans.
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NFE2L2 – 653A/G genotype and vasodilator responses in African Americans. Forearm
blood flow (a, c) and forearm vascular resistance (b, d) at baseline and upon the
administration of bradykinin (a, b) or sodium nitroprusside (c, d) were determined using a
dominant model of inheritance. Results are presented as mean±SEM. The repeated-measures
ANOVA P and F values for each comparison are provided. *Post hoc (P<0.05) versus wild-
type (A/A). ANOVA, analysis of variance.
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NFE2L2 – 653A/G genotype and vasodilator responses in whites. Forearm blood flow (a, c)
and forearm vascular resistance (b, d) at baseline and upon the administration of bradykinin
(a, b) or sodium nitroprusside (c, d) were determined using an additive model of inheritance.
Results are presented as mean±SEM. The repeated-measures ANOVA P and F values for
each comparison are provided. *Post hoc (P<0.05) versus wild-type (A/A). ANOVA,
analysis of variance.
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NFE2L2 – 617C/A genotype and vasodilator responses in whites. Forearm blood flow (a, c)
and forearm vascular resistance (b, d) at baseline and upon the administration of bradykinin
(a, b) or sodium nitroprusside (c, d) were determined using a dominant model of inheritance.
Results are presented as mean±SEM. The repeated-measures ANOVA P and F values for
each comparison are provided. *Post hoc (P<0.05) versus wild-type (C/C). ANOVA,
analysis of variance.
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Functional significance of the NFE2L2 promoter polymorphisms in vitro. The relative
luciferase activity of NFE2L2 promoter constructs after exposure to vehicle (basal
conditions), bradykinin (0.01 or 0.1 mmol/l), sodium nitroprusside (0.1 mmol/l), or
hydrogen peroxide (0.1 mmol/l) was compared following transient transfection in human
microvascular endothelial cells (HMVEC). The sequence identifies the three polymorphisms
studied (– 653A/G, –651A/G, and – 617C/A) and putative transcription factor-binding sites
including the myeloid zinc finger-1 (MZF1)/stress response element (StRE), an AP-1-like
sequence, and the antioxidant response element (ARE). Luciferase activity was expressed
relative to the wild-type (WT) vehicle group. *Post hoc (P<0.05) compared with the vehicle
(within each genotype group); +Post hoc (P<0.05) compared with WT (within each
treatment group).
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Table 1
Participant characteristics by race
Variable African Americans Whites
N 64 184
Age (years) 32.9±1.3 31.6±0.8
Females (%) 39 (60.9%) 80 (43.5%)*
BMI (kg/m2) 26.1±0.4 24.6±0.3*
Smoker (% yes) 4 (6.3%) 19 (10.3%)
MAP (mmHg) 87.3±1.2 83.5±0.7*
HR (bpm) 64±1.4 65±0.8
FBF (ml/100 ml tissue/min) 3.6±1.1 3.8±1.0
FVR (mmHg/ml/100 ml tissue/min) 25.2±1.1 21.8±1.0*
Data are presented as mean±SEM or count (proportion).
FBF, baseline forearm blood flow; FVR, baseline forearm vascular resistance; HR, heart rate; MAP, mean arterial pressure.
*
P <0.05 versus African Americans.
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